Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study

Bibliography

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14
   PubMed Web of Science ®Google Scholar
• Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci (Lond) 2006;110(2):143-52
   PubMedGoogle Scholar
• Derosa G, D'Angelo A, Salvadeo SA, Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Horm Metab Res 2010;42(1):8-13
   PubMedGoogle Scholar
• Derosa G, D'Angelo A, Salvadeo SA, Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res 2010;79(2):144-9
   PubMedGoogle Scholar
• Derosa G, Cicero AF, Fogari E, Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res 2011;43(7):505-12
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, D'Angelo A, Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. J Diabetes Complications 2011;25(4):258-66
   PubMedGoogle Scholar
• Derosa G, Maffioli P, Ferrari I, Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011;651(1-3):240-50
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012;14(4):350-64
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010;42(9):663-9
   PubMed Web of Science ®Google Scholar
• Maeda S, Matsui T, Yamagishi SI. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol 2012;158(1):171-3
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M, Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1):88-136
   PubMed Web of Science ®Google Scholar
• Lichtenstein AH, Appel LJ, Brands M, Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91
   PubMed Web of Science ®Google Scholar
• Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-7
   PubMed Web of Science ®Google Scholar
• European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
   PubMed Web of Science ®Google Scholar
• Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95
   PubMed Web of Science ®Google Scholar
• Houssa P, Dinensen B, Deberg M, First direct assay for intact human proinsulin. Clin Chem 1998;44(7):1514-19
   PubMed Web of Science ®Google Scholar
• El Kenz H, Bergmann P. Evaluation of immunochemiluminometric assays for the measurement of insulin and C-peptide using the ADVIA Centaur. Clin Lab 2004;50:171-4
   PubMedGoogle Scholar
• Holst JJ. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982;207:381-8
   PubMed Web of Science ®Google Scholar
• Yannakoulia M, Yiannakouris N, Bluher S, Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88(4):1730-6
   PubMedGoogle Scholar
• Takebayashi K, Suetsugu M, Wakabayashi S, Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007;92(7):2712-19
   PubMedGoogle Scholar
• MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell Metab 2007;6:159-61
   PubMed Web of Science ®Google Scholar
• Zhang M, Tracey K. The cytokine handbook. 3rd edition. Academic Press; San Diego, USA: 1988
   Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Corner A, One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-8
   PubMed Web of Science ®Google Scholar
• Fasching P, Ratheiser K, Nowotny P, Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 1994;43:385-9
   PubMedGoogle Scholar
• Winer BJ. Statistical principles in experimental design. 2nd edition. McGraw-Hill; New York: 1971
   Google Scholar
• Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther 2010;12:491-501
   PubMed Web of Science ®Google Scholar
• Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009;11:1091-9
   PubMed Web of Science ®Google Scholar
• Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945-61
   PubMed Web of Science ®Google Scholar
• Mari A, Sallas WM, He YL, Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94
   PubMed Web of Science ®Google Scholar
• He YL, Wang Y, Bullock JM, Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633-41
   PubMed Web of Science ®Google Scholar
• D'Alessio DA, Denney AM, Hermiller LM, Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009;94:81-8
   PubMed Web of Science ®Google Scholar
• Ward WK, Bolgiano DC, McKnight B, Diminished beta-cell secretory capacity in patients with non insulin dependent diabetes mellitus. J Clin Invest 1984;74:1318-28
   PubMed Web of Science ®Google Scholar
• Foley JE, Bunck MC, Moller-Goede DL, Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011;54:1985-91
   PubMedGoogle Scholar
• Derosa G, Ragonesi PD, Carbone A, Vildagliptin added to metformin on ?-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther 2012;14(6):475-84
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, Franzetti I, Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, beta-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012;98(1):51-60
   PubMedGoogle Scholar
• Derosa G, Carbone A, D'angelo A, A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opin Pharmacother 2012; doi:10.1517/14656566.2012.730519
   Google Scholar
• Azuma K, Oguchi S, Matsubara Y, Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 2004;36(8):564-70
   PubMedGoogle Scholar
• Bouchard L, Weisnagel SJ, Engert JC, Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Quebec Family Study. J Endocrinol Invest 2004;27(11):1003-9
   PubMedGoogle Scholar
• McTernan PG, Fisher FM, Valsamakis G, Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88(12):6098-106
   PubMedGoogle Scholar
• Ohmori R, Momiyama Y, Kato R, Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005;46(2):379-80
   PubMedGoogle Scholar
• Yang Q, Graham TE, Mody N, Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436(7049):356-62
   PubMed Web of Science ®Google Scholar
• Wittamer V, Franssen JD, Vulcano M, Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198(7):977-85
   PubMed Web of Science ®Google Scholar
• Bozaoglu K, Bolton K, McMillan J, Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148(10):4687-94
   PubMed Web of Science ®Google Scholar
• Goralski KB, McCarthy TC, Hanniman EA, Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282(38):28175-88
   PubMed Web of Science ®Google Scholar
• Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389(6651):610-14
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259(5091):87-91
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5
   PubMed Web of Science ®Google Scholar